JP7241353B2 - 肺腺癌のサブタイピングのための方法 - Google Patents

肺腺癌のサブタイピングのための方法 Download PDF

Info

Publication number
JP7241353B2
JP7241353B2 JP2019512944A JP2019512944A JP7241353B2 JP 7241353 B2 JP7241353 B2 JP 7241353B2 JP 2019512944 A JP2019512944 A JP 2019512944A JP 2019512944 A JP2019512944 A JP 2019512944A JP 7241353 B2 JP7241353 B2 JP 7241353B2
Authority
JP
Japan
Prior art keywords
hla
expression
classifier
sample
subtype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019512944A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019516407A (ja
JP2019516407A5 (enExample
Inventor
ハワジン ファルキ，
マイラ ライ－ゴールドマン，
グレッグ メイヒュー，
ジョナサン セロディー，
チャールズ ペロウ，
デイビッド ニール ヘイズ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of JP2019516407A publication Critical patent/JP2019516407A/ja
Publication of JP2019516407A5 publication Critical patent/JP2019516407A5/ja
Application granted granted Critical
Publication of JP7241353B2 publication Critical patent/JP7241353B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019512944A 2016-05-17 2017-05-17 肺腺癌のサブタイピングのための方法 Active JP7241353B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201662337591P 2016-05-17 2016-05-17
US201662337645P 2016-05-17 2016-05-17
US62/337,645 2016-05-17
US62/337,591 2016-05-17
US201662396587P 2016-09-19 2016-09-19
US62/396,587 2016-09-19
US201662420836P 2016-11-11 2016-11-11
US62/420,836 2016-11-11
US201662425717P 2016-11-23 2016-11-23
US62/425,717 2016-11-23
PCT/US2017/033110 WO2017201165A1 (en) 2016-05-17 2017-05-17 Methods for subtyping of lung adenocarcinoma

Publications (3)

Publication Number Publication Date
JP2019516407A JP2019516407A (ja) 2019-06-20
JP2019516407A5 JP2019516407A5 (enExample) 2020-07-02
JP7241353B2 true JP7241353B2 (ja) 2023-03-17

Family

ID=60326094

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019512944A Active JP7241353B2 (ja) 2016-05-17 2017-05-17 肺腺癌のサブタイピングのための方法

Country Status (6)

Country Link
US (2) US10934595B2 (enExample)
EP (1) EP3458612B1 (enExample)
JP (1) JP7241353B2 (enExample)
CN (2) CN116987790A (enExample)
CA (1) CA3024747A1 (enExample)
WO (1) WO2017201165A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3149209B1 (en) 2014-05-30 2021-02-17 Genecentric Therapeutics, Inc. Methods for typing of lung cancer
US10934595B2 (en) 2016-05-17 2021-03-02 Genecentric Therapeutics, Inc. Methods for subtyping of lung adenocarcinoma
CA3024744A1 (en) 2016-05-17 2017-11-23 Genecentric Therapeutics, Inc. Methods for subtyping of lung squamous cell carcinoma
EP4628895A3 (en) * 2017-01-13 2025-12-17 Mayo Foundation for Medical Education and Research Materials and methods for treating cancer
KR102802863B1 (ko) * 2017-12-01 2025-04-30 일루미나, 인코포레이티드 약물 효능을 평가하기 위한 시스템 및 방법
US12266426B2 (en) 2017-12-01 2025-04-01 Illumina, Inc. Method for administering a cancer treatment
US12195805B2 (en) 2018-02-13 2025-01-14 Genecentric Therapeutics, Inc. Methods for subtyping of bladder cancer
US11414698B2 (en) * 2018-03-22 2022-08-16 Chang Gung Medical Foundation Chang Gung Memorial Hospital At Chiayi Method of quantifying mutant allele burden of target gene
CA3105292A1 (en) * 2018-08-10 2020-02-13 Omniseq, Inc. Methods and systems for assessing proliferative potential and resistance to immune checkpoint blockade
WO2020076897A1 (en) 2018-10-09 2020-04-16 Genecentric Therapeutics, Inc. Detecting cancer cell of origin
WO2020081463A1 (en) * 2018-10-18 2020-04-23 Verily Life Sciences Llc Systems and methods for using image processing to generate inferences of biomarker for immunotherapy
CN112442535A (zh) * 2019-08-27 2021-03-05 上海善准生物科技有限公司 原发性肺腺癌分子分型及生存风险基因群及诊断产品和应用
BR112022004952A2 (pt) * 2019-10-11 2022-06-28 Bioventures Llc Uso de detecção simultânea de marcadores para avaliação de glioma difuso e capacidade de resposta a tratamento
CN112034185A (zh) * 2020-09-11 2020-12-04 上海市胸科医院 Gpr110、vegfr、cd34在鉴别肺腺癌亚型中的用途
CN112530595A (zh) * 2020-12-21 2021-03-19 无锡市第二人民医院 一种基于多分支链式神经网络的心血管疾病分类方法和装置
US20240182984A1 (en) * 2021-03-30 2024-06-06 Genecentric Therapeutics, Inc. Methods for assessing proliferation and anti-folate therapeutic response
CN113687076B (zh) * 2021-07-14 2024-03-01 郑州大学 一种可用于肺腺癌早期诊断的联合检测血清标志物及其应用
WO2023010327A1 (zh) * 2021-08-04 2023-02-09 杭州浙大迪迅生物基因工程有限公司 一种人白三烯受体CysLTR2 mRNA RT-PCR检测用引物探针组和试剂盒
CN113903400B (zh) * 2021-10-29 2024-10-01 复旦大学附属华山医院 免疫相关疾病分子分型和亚型分类器的分类方法、系统
CN113981093B (zh) * 2021-11-26 2023-06-16 大连医科大学附属第一医院 Inpp4b基因表达量的检测剂在制备用于预测肺腺癌放疗敏感性的试剂盒的应用
CN114480644A (zh) * 2022-01-07 2022-05-13 深圳市龙华区人民医院 肺腺癌基于代谢基因的分子分型
CN114574589B (zh) * 2022-04-28 2022-08-16 深圳市第二人民医院(深圳市转化医学研究院) 标志物znf207在制备肺腺癌诊断试剂中的应用及诊断试剂盒
US20250327132A1 (en) * 2022-06-13 2025-10-23 The Government of the United States, as represented by the Director of the Defense Health Agency Lung Cancer-Related Biomarkers and Methods of Using the Same
CN115896282A (zh) * 2022-08-02 2023-04-04 上海市同仁医院 一种对甲状腺微小乳头状癌进行分子分型的方法以及分子标志物应用
CN115862876B (zh) * 2023-03-02 2023-05-26 北京师范大学 基于免疫微环境基因群预测肺腺癌患者预后的装置
CN116403648B (zh) * 2023-06-06 2023-08-01 中国医学科学院肿瘤医院 一种基于多维分析建立的小细胞肺癌免疫新分型方法
CN117491636A (zh) * 2023-11-21 2024-02-02 郑州大学 一种用于肺癌诊断的生物标志物及其应用
CN117635612A (zh) * 2024-01-25 2024-03-01 天津博思特医疗科技有限责任公司 一种肺部ct图像的识别方法
CN118460691B (zh) * 2024-07-11 2024-10-15 浙江省血液中心 用于hla基因多重扩增的引物组合物、应用和基因分型方法
CN119876392B (zh) * 2025-01-06 2025-08-12 上海市第六人民医院 一种用于辅助诊断肺腺癌骨转移的生物标志物
CN120445960A (zh) * 2025-05-07 2025-08-08 广州医科大学附属第一医院（广州呼吸中心） 一种外泌体表面标志物鉴别乳腺癌亚型的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015173267A1 (en) 2014-05-13 2015-11-19 Medimmune Limited Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
JP2018512160A (ja) 2015-04-14 2018-05-17 ジーンセントリック セラピューティクス， インコーポレイテッド 肺がんのタイピングのための方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
CA2118806A1 (en) 1991-09-18 1993-04-01 William J. Dower Method of synthesizing diverse collections of oligomers
AU675054B2 (en) 1991-11-22 1997-01-23 Affymetrix, Inc. Combinatorial strategies for polymer synthesis
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
DE69829402T2 (de) 1997-10-31 2006-04-13 Affymetrix, Inc. (a Delaware Corp.), Santa Clara Expressionsprofile in adulten und fötalen organen
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US6670321B1 (en) 1998-12-30 2003-12-30 The Children's Medical Center Corporation Prevention and treatment for retinal ischemia and edema
AU2002226912A1 (en) 2000-11-16 2002-05-27 Cedars-Sinai Medical Center Profiling tumor specific markers for the diagnosis and treatment of neoplastic disease
US7473767B2 (en) 2001-07-03 2009-01-06 The Institute For Systems Biology Methods for detection and quantification of analytes in complex mixtures
AU2002343443A1 (en) 2001-09-28 2003-04-14 Whitehead Institute For Biomedical Research Classification of lung carcinomas using gene expression analysis
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
JP2007006792A (ja) * 2005-06-30 2007-01-18 Hitachi Software Eng Co Ltd 肺腺癌の胸膜浸潤を判別するための遺伝子セット
WO2008151110A2 (en) 2007-06-01 2008-12-11 The University Of North Carolina At Chapel Hill Molecular diagnosis and typing of lung cancer variants
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
CA2726531A1 (en) * 2008-06-05 2009-12-10 University Health Network Compositions and methods for classifying lung cancer and prognosing lung cancer survival
CN101509035A (zh) 2008-09-05 2009-08-19 中国人民解放军总医院 肺癌分型的基因序列及其应用
WO2013172926A1 (en) 2012-05-14 2013-11-21 Yale University Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer
WO2013192089A1 (en) 2012-06-18 2013-12-27 The University Of North Carolina At Chapel Hill Methods for head and neck cancer prognosis
EP2806274A1 (en) 2013-05-24 2014-11-26 AIT Austrian Institute of Technology GmbH Lung cancer diagnostic method and means
US20150057335A1 (en) * 2013-08-20 2015-02-26 National Cancer Center Novel fusion genes identified in lung cancer
US9885721B2 (en) * 2014-05-29 2018-02-06 Spring Bioscience Corporation PD-L1 antibodies and uses thereof
EP3149209B1 (en) 2014-05-30 2021-02-17 Genecentric Therapeutics, Inc. Methods for typing of lung cancer
US10934595B2 (en) 2016-05-17 2021-03-02 Genecentric Therapeutics, Inc. Methods for subtyping of lung adenocarcinoma
CA3024744A1 (en) 2016-05-17 2017-11-23 Genecentric Therapeutics, Inc. Methods for subtyping of lung squamous cell carcinoma
WO2019018764A1 (en) * 2017-07-21 2019-01-24 Genecentric Therapeutics, Inc. METHODS OF DETERMINING RESPONSE TO PARP INHIBITORS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015173267A1 (en) 2014-05-13 2015-11-19 Medimmune Limited Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
JP2018512160A (ja) 2015-04-14 2018-05-17 ジーンセントリック セラピューティクス， インコーポレイテッド 肺がんのタイピングのための方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Clin.Cancer Res.,Jan.2016,Vol.22,No.1,p.218-229
J.Clin.Oncol.,2006,Vol.24,No.31,p.5079-5090
J.Thoracic Oncol.,2017,Vol.12,No.6,p.943-953
Nature,2014,Vol.511,p.543-550
PLoS ONE,2012,Vol.7,No.5,e36530,p.1-13
肺がんの新規免疫療法，免疫療法ニュースピックアップ，https://web.archive.org/web/20160313081253/https://www.gan-info.jp/dendritic/newspickup/article02/，[Online]，２０１６年３月１３日，［２０２１年４月１４日検索］

Also Published As

Publication number Publication date
CN109790583B (zh) 2023-08-25
US20190338365A1 (en) 2019-11-07
CA3024747A1 (en) 2017-11-23
EP3458612B1 (en) 2023-11-15
US20210222254A1 (en) 2021-07-22
EP3458612A1 (en) 2019-03-27
JP2019516407A (ja) 2019-06-20
CN116987790A (zh) 2023-11-03
US10934595B2 (en) 2021-03-02
CN109790583A (zh) 2019-05-21
WO2017201165A1 (en) 2017-11-23
US12139763B2 (en) 2024-11-12
EP3458612A4 (en) 2020-02-26

Similar Documents

Publication Publication Date Title
JP7241353B2 (ja) 肺腺癌のサブタイピングのための方法
JP7241352B2 (ja) 肺扁平上皮癌のサブタイピングのための方法
US20220243283A1 (en) Methods for typing of lung cancer
US11851715B2 (en) Detecting cancer cell of origin
US12006554B2 (en) Methods for subtyping of head and neck squamous cell carcinoma
EP3149209B1 (en) Methods for typing of lung cancer
US11739386B2 (en) Methods for determining response to PARP inhibitors
US12195805B2 (en) Methods for subtyping of bladder cancer
WO2023164595A2 (en) Methods for subtyping and treatment of head and neck squamous cell carcinoma
HK40006868B (en) Methods for subtyping of lung adenocarcinoma
HK40006868A (en) Methods for subtyping of lung adenocarcinoma
HK40006869A (en) Methods for subtyping of lung squamous cell carcinoma
HK40006869B (en) Methods for subtyping of lung squamous cell carcinoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200518

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210517

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210812

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221207

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230227

R150 Certificate of patent or registration of utility model

Ref document number: 7241353

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150